Gene Center Munich
print


Breadcrumb Navigation


Content

Subklewe Lab - Translational Cancer Immunology

Research Topics

  • Novel Target Antigens
  • Antibodies + CAR-T Cells
  • Vaccination + Checkpoint Blockade
  • Immune Monitoring + Biomarkers

twitter_banner


Prof. Marion Subklewe

phone: +49 (0)89 - 4400 73133
subklewe@genzentrum.lmu.de

The Laboratory for Translational Cancer Immunology develops immunotherapies for malignant neoplasia, with a special focus on acute leukemia and B-cell lymphoma. We seek to understand mechanisms of action and resistance of cellular- and antibody-based immunotherapy. The goal is to identify predictive biomarkers for selecting the suitable immunotherapy for each individual patient. Read more...

Selected Publications

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals.
Zieger N, Kazerani M, Nicholls A, Vick B, Wulf J, Straub T, Scheurer M, Muth A, Hänel G, Nixdorf D, Sponheimer M, Ohlmeyer M, Lacher SM, Brauchle B, Marcinek A, Rohrbacher L, Leutbecher A, Rejeski K, Weigert O, von Bergwelt-Baildon M, Theurich S, Kischel R, Jeremias I, Bücklein VL, Subklewe M.
Blood. 2022 Jul 25:blood.2022015956. doi: 10.1182/blood.2022015956. Online ahead of print. PubMed

Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC specific T-cell bispecific antibody.
Augsberger C, Hänel G, Xu W, Pulko V, Hanisch L, Augustin A, Challier J, Hunt K, Vick B, Rovatti P, Krupka C, Rothe M, Schönle A, Sam J, Lezan E, Ducret A, Ortiz-Franyuti D, Walz A, Benz J, Bujotzek A, Lichtenegger FS, Gassner C, Carpy A, Lyamichev V, Patel J, Konstandin N, Tunger A, Schmitz M, von Bergwelt-Baildon M, Spiekermann K, Vago L, Jeremias I, Marrer-Berger E, Umaña P, Klein C, Subklewe M.
Blood. 2021 Dec 23;138(25):2655-2669. doi: 10.1182/blood.2020010477. PubMed

CAR-HEMATOTOX: A model for CAR T-cell related hematological toxicity in relapsed/refractory large B-cell lymphoma.
Rejeski K, Perez Perez A, Sesques P, Hoster E, Berger CS, Jentzsch L, Mougiakakos D, Frölich L, Ackermann J, Buecklein V, Blumenberg V, Schmidt C, Jallades L, Fehse B, Faul C, Karschnia P, Weigert O, Dreyling M, Locke FL, von Bergwelt-Baildon M, Mackensen A, Bethge WA, Ayuk F, Bachy E, Salles GA, Jain MD, Subklewe M.
Blood. 2021 Dec 16;138(24):2499-2513. doi: 10.1182/blood.2020010543. PubMed

Toll-like receptor 7/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trial.
Lichtenegger FS, Schnorfeil FM, Rothe M, Deiser K, Altmann T, Bücklein VL, Köhnke T, Augsberger C, Konstandin NP, Spiekermann K, Moosmann A, Boehm S, Boxberg M, Heemskerk MH, Goerlich D, Wittmann G, Wagner B, Hiddemann W, Schendel DJ, Kvalheim G, Bigalke I, Subklewe M.
Clin Transl Immunology. 2020 Mar 3;9(3):e1117. doi: 10.1002/cti2.1117. PubMed

Bifunctional PD-1 x αCD3 x αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia.
Herrmann M, Krupka C, Deiser K, Brauchle B, Marcinek A, Ogrinc Wagner A, Rataj F, Mocikat R, Metzeler KH, Spiekermann K, Kobold S, Fenn NC, Hopfner KP, Subklewe M.
Blood. 2018 Dec 6;132(23):2484-2494. doi: 10.1182/blood-2018-05-849802. Epub 2018 Oct 1. PubMed

Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells.
Lichtenegger FS, Rothe M, Schnorfeil FM, Deiser K, Krupka C, Augsberger C, Schlüter M, Neitz J, Subklewe M.
Front Immunol. 2018 Feb 27;9:385. doi: 10.3389/fimmu.2018.00385. PubMed

More publications